Shilpa Medicare gets Germany marketing authorization for Amifampridine Tablets
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-01-20 07:00 GMT | Update On 2024-03-26 10:06 GMT
Advertisement
Hyderabad: Shilpa Medicare Limited has received Marketing Authorization from Germany, EU for Amifampridine Tablets, 10 mg under the National Procedure.
Amifampridine is used as a drug, predominantly in the treatment of a number of rare muscle diseases. Specifically, Amifampridine is used to treat Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disease.
This product has sales of about 20 M USD in Europe. As on date, there is one other approved generic in the market.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.